[
  {
    "ts": "2025-12-22T00:13:09+00:00",
    "headline": "Dow Jones Futures Rise; Palantir, GE Lead 12 Stocks In Buy Zones",
    "summary": "Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-bullish-palantir-ge-stocks-in-buy-zones/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "80a2ea9c-2db3-3528-b01e-3c1d9015e4c7",
      "content": {
        "id": "80a2ea9c-2db3-3528-b01e-3c1d9015e4c7",
        "contentType": "STORY",
        "title": "Dow Jones Futures Rise; Palantir, GE Lead 12 Stocks In Buy Zones",
        "description": "",
        "summary": "Bearish conditions on Wednesday turned bullish by Friday's close, with the S&P 500 and Nasdaq back above their 50-day lines. Palantir and GE lead a slew of new buys.",
        "pubDate": "2025-12-22T00:13:09Z",
        "displayTime": "2025-12-22T00:13:09Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/80a2ea9c-2db3-3528-b01e-3c1d9015e4c7/dow-jones-futures-rise-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/6110bd4e4da5de8873d1cebd0418528c",
          "originalWidth": 1012,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xoK4GRTZCRK805ljxI.dHQ--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/6110bd4e4da5de8873d1cebd0418528c.cf.webp",
              "width": 1012,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bYzIyHaIDBJI64RoG9LAbw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/6110bd4e4da5de8873d1cebd0418528c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-bullish-palantir-ge-stocks-in-buy-zones/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "MU"
            },
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "GE"
            },
            {
              "symbol": "^NDX"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "RTX"
            },
            {
              "symbol": "LRCX"
            },
            {
              "symbol": "SHOP"
            },
            {
              "symbol": "AXSM"
            },
            {
              "symbol": "GMAB"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "SNDK"
            },
            {
              "symbol": "KLAC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T07:16:00+00:00",
    "headline": "Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer",
    "summary": "Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a major challenge for most melanoma and lung cancer patients TURKU, FI / ACCESS Newswire / December 22, 2025 ...",
    "url": "https://finance.yahoo.com/news/faron-announces-strategic-collaboration-institute-071600168.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "87ac9d9f-15d0-330e-8529-9cb9d75e95fd",
      "content": {
        "id": "87ac9d9f-15d0-330e-8529-9cb9d75e95fd",
        "contentType": "STORY",
        "title": "Faron Announces Strategic Collaboration with The Institute for Cancer Research to Launch BLAZE Trial, Targeting Immunotherapy Resistance in Cancer",
        "description": "",
        "summary": "Investigator-initiated trial aims to provide proof-of-concept for bexmarilimab in overcoming acquired resistance to checkpoint inhibitors, a major challenge for most melanoma and lung cancer patients TURKU, FI / ACCESS Newswire / December 22, 2025 ...",
        "pubDate": "2025-12-22T07:16:00Z",
        "displayTime": "2025-12-22T07:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/faron-announces-strategic-collaboration-institute-071600168.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/faron-announces-strategic-collaboration-institute-071600168.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "FARON.HE"
            },
            {
              "symbol": "FARN.L"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:00:00+00:00",
    "headline": "Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes",
    "summary": "FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio",
    "url": "https://finance.yahoo.com/news/gilead-sciences-exercises-option-license-130000311.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "652f8bcf-21fd-3987-a39e-4d5d45bd7f14",
      "content": {
        "id": "652f8bcf-21fd-3987-a39e-4d5d45bd7f14",
        "contentType": "STORY",
        "title": "Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes",
        "description": "",
        "summary": "FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio",
        "pubDate": "2025-12-22T13:00:00Z",
        "displayTime": "2025-12-22T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/17c4384e6a29db83343bb11bb3e5cbda",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/azrFKvrent2ZbY0vZPNBAw--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/17c4384e6a29db83343bb11bb3e5cbda.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iDxT6O2R7bp.B2tfm_uP6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/17c4384e6a29db83343bb11bb3e5cbda.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-exercises-option-license-130000311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-exercises-option-license-130000311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "ASMB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]